Abstract: Targeted gene therapy has become a promising approach for lung cancer treatment. In our previous work, we reported that the targeted expression of microRNA-7 (miR-7) operated by thyroid transcription factor-1 (TTF-1) promoter inhibited the growth of human lung cancer cells in vitro and in vivo; however, the intervention efficiency needed to be further improved. In this study, we identified the core promoter of TTF-1 (from -1299 bp to -871 bp) by 5' deletion assay and screened out the putative transcription factors nuclear factor-1 (NF-1) and activator protein-1 (AP-1). Further analysis revealed that the expression level of NF-1, but not AP-1, was positively connected with the activation of TTF-1 core promoter in human non-small-cell lung cancer (NSCLC) cells. Moreover, the silencing of NF-1 could reduce the expression level of miR-7 operated by TTF-1 core promoter. Of note, we optimized four distinct sequences to form additional NF-1-binding sites (TGGCA) in the sequence of TTF-1 core promoter (termed as ^optTTF-1 promoter), and verified the binding efficiency of NF-1 on the ^optTTF-1 promoter by electrophoretic mobility shift assay (EMSA). As expected, the ^optTTF-1 promoter could more effectively drive miR-7 expression and inhibit the growth of human NSCLC cells in vitro, accompanied by a reduced transduction of NADH dehydrogenase (ubiquinone) 1α subcomplex 4 (NDUFA4)/protein kinase B (Akt) pathway. Consistently, ^optTTF-1 promoter-driven miR-7 expression could also effectively abrogate the growth and metastasis of tumor cells in a murine xenograft model of human NSCLC. Finally, no significant changes were detected in the biological indicators or the histology of some important tissues and organs, including heart, liver, and spleen. On the whole, our study revealed that the optimized TTF-1 promoter could more effectively operate miR-7 to influence the growth of human NSCLC cells, providing a new basis for the development of microRNA-based targeting gene therapy against clinical lung cancer.

优化的TTF-1核心启动子驱动miRNA-7表达有效抑制人非小细胞肺癌细胞的生长

[1]AmreddyN, BabuA, MuralidharanR, et al., 2017. Polymeric nanoparticle-mediated gene delivery for lung cancer treatment. Top Curr Chem (Cham), 375(2):35.

[2]BillietC, PeetersS, DecaluwéH, et al., 2016. Postoperative radiotherapy for lung cancer: is it worth the controversy? Cancer Treat Rev, 51:10-18.

[3]BucherK, Rodríguez-BocanegraE, DauletbekovD, et al., 2021. Immune responses to retinal gene therapy using adeno-associated viral vectors-implications for treatment success and safety. Prog Retin Eye Res, 83:100915.

[4]CaoQ, MaoZD, ShiYJ, et al., 2016. MicroRNA-7 inhibits cell proliferation, migration and invasion in human non-small cell lung cancer cells by targeting FAK through ERK/MAPK signaling pathway. Oncotarget, 7(47):77468-77481.

[5]ChanBA, CowardJIG, 2013. Chemotherapy advances in small-cell lung cancer. J Thorac Dis, 5(S5):S565-S578.

[6]ChandlerRJ, VenturoniLE, LiaoJ, et al., 2021. Promoterless, nuclease-free genome editing confers a growth advantage for corrected hepatocytes in mice with methylmalonic acidemia. Hepatology, 73(6):2223-2237.

[7]ChenHZ, GuoMM, YueDX, et al., 2021. MicroRNA-7 negatively regulates Toll-like receptor 4 signaling pathway through FAM177A. Immunology, 162(1):44-57.

[8]ChenSP, WangY, LiDM, et al., 2022. Mechanisms controlling microRNA expression in tumor. Cells, 11(18):2852.

[9]DaninoYM, EvenD, IdesesD, et al., 2015. The core promoter: at the heart of gene expression. Biochim Biophys Acta, 1849(8):1116-1131.

[10]DuX, XiaoJJ, FuXF, et al., 2021. A proteomic analysis of Bcl-2 regulation of cell cycle arrest: insight into the mechanisms. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(10):839-855.

[11]DuX, ZhangJQ, LiuL, et al., 2022. A novel anticancer prop

[12]erty of Lycium barbarum polysaccharide in triggering ferroptosis of breast cancer cells. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(4):286-299.

[13]DziadziuszkoR, KrebsMG, de BraudF, et al., 2021. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol, 39(11):1253-1263.

[14]EvenDY, KedmiA, IdesesD, et al., 2017. Functional screening of core promoter activity. In: Gould D (Ed.), Mammalian Synthetic Promoters. Humana, New York, p.77-91.

[15]FukazawaT, MaedaY, DurbinML, et al., 2007. Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system. Mol Cancer Ther, 6(1):244-252.

[16]FulzeleSV, ChatterjeeA, ShaikMS, et al., 2006. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm Res, 23(9):2094-2106.

[17]GuanL, ZhaoX, TangL, et al., 2021. Thyroid transcription factor-1: structure, expression, function and its relationship with disease. Biomed Res Int, 2021:9957209.

[18]HuangQM, ZengYM, LinHH, et al., 2017. Transfection with Livin and Survivin shRNA inhibits the growth and proliferation of non-small cell lung cancer cells. Mol Med Rep, 16(5):7086-7091.

[19]IkedaK, Shaw-WhiteJR, WertSE, et al., 1996. Hepatocyte nuclear factor 3 activates transcription of thyroid transcription factor 1 in respiratory epithelial cells. Mol Cell Biol, 16(7):3626-3636.

[20]KimJH, KimHS, KimBJ, et al., 2018. Prognostic impact of TTF-1 expression in non-squamous non-small-cell lung cancer: a meta-analysis. J Cancer, 9(22):4279-4286.

[21]KizzireK, KharghariaS, RiceKG, 2013. High-affinity PEGylated polyacridine peptide polyplexes mediate potent in vivo gene expression. Gene Ther, 20(4):407-416.

[22]Lara-GuerraH, RothJA, 2016. Gene therapy for lung cancer. Crit Rev Oncog, 21(1-2):115-124.

[23]LeeAY, ChoMH, KimS, 2019. Recent advances in aerosol gene delivery systems using non-viral vectors for lung cancer therapy. Expert Opin Drug Deliv, 16(7):757-772.

[24]LeiLY, ChenC, ZhaoJJ, et al., 2017. Targeted expression of miR-7 operated by TTF-1 promoter inhibited the growth of human lung cancer through the NDUFA4 pathway. Mol Ther Nucleic Acids, 6:183-197.

[25]LiC, WuX, ZhangW, et al., 2014. AEG-1 promotes metastasis through downstream AKR1C2 and NF1 in liver cancer. Oncol Res, 22(4):203-211.

[26]LiC, BrantE, BudakH, et al., 2021. CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(4):253-284.

[27]LiJR, ZhengYJ, SunGY, et al., 2014. Restoration of miR-7 expression suppresses the growth of Lewis lung cancer cells by modulating epidermal growth factor receptor signaling. Oncol Rep, 32(6):2511-2516.

[28]LiY, EggermontK, VanslembrouckV, et al., 2013. NKX2-1 activation by SMAD2 signaling after definitive endoderm differentiation in human embryonic stem cell. Stem Cells Dev, 22(9):1433-1442.

[29]Linnerth-PetrikNM, SantryLA, YuDL, et al., 2012. Adeno-associated virus vector mediated expression of an oncogenic retroviral envelope protein induces lung adenocarcinomas in immunocompetent mice. PLoS ONE, 7(12):e51400.

[30]LiuZL, JiangZM, HuangJY, et al., 2014. miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways. Int J Oncol, 44(5):1571-1580.

[31]LuxCT, ScharenbergAM, 2017. Therapeutic gene editing safety and specificity. Hematol Oncol Clin North Am, 31(5):787-795.

[32]MassaroG, HughesMP, WhalerSM, et al., 2020. Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes. Hum Mol Genet, 29(12):1933-1949.

[33]NakazatoM, ChungHK, UlianichL, et al., 2000. Thyroglobulin repression of thyroid transcription factor 1 (TTF-1) gene expression is mediated by decreased DNA binding of nuclear factor I proteins which control constitutive TTF-1 expression. Mol Cell Biol, 20(22):8499-8512.

[34]NaldiniL, 2015. Gene therapy returns to centre stage. Nature, 526(7573):351-360.

[35]NasimF, SabathBF, EapenGA, 2019. Lung cancer. Med Clin North Am, 103(3):463-473.

[36]PhilpottC, TovellH, FraylingIM, et al., 2017. The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics, 11:13.

[37]PowellSK, Rivera-SotoR, GraySJ, 2015. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov Med, 19(102):49-57.

[38]PrullerJ, HoferI, GanassiM, et al., 2021. A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy. Cancer Gene Ther, 28(5):427-441.

[39]QianB, WangDM, GuXS, et al., 2018. LncRNA H19 serves as a ceRNA and participates in non-small cell lung cancer development by regulating microRNA-107. Eur Rev Med Pharmacol Sci, 22(18):5946-5953.

[40]RaiKM, TakigawaN, ItoS, et al., 2011. Liposomal delivery of microRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther, 10(9):1720-1727.

[41]SebestyénMG, BudkerVG, BudkerT, et al., 2006. Mechanism of plasmid delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of various molecules. J Gene Med, 8(7):852-873.

[42]SheikhS, ErnstD, KeatingA, 2021. Prodrugs and prodrug-activated systems in gene therapy. Mol Ther, 29(5):1716-1728.

[43]SherYP, TzengTF, KanSF, et al., 2009. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival. Oncogene, 28(37):3286-3295.

[44]SuJC, RuanSL, DaiSK, et al., 2019. NF1 regulates apoptosis in ovarian cancer cells by targeting MCL1 via miR-142-5p. Pharmacogenomics, 20(3):155-165.

[45]TolozaEM, MorseMA, LyerlyHK, 2006. Gene therapy for lung cancer. J Cell Biochem, 99(1):1-22.

[46]UmakanthanS, BukeloMM, 2021. Concise genetic profile of lung carcinoma. Postgrad Med J, 0:1-5.

[47]UmakanthanS, RaoAVC, MohammedW, 2021. Role of immunohistochemistry markers in neoplastic lung lesions. J Cancer Res Ther, 17(6):1382-1388.

[48]WigginsJF, RuffinoL, KelnarK, et al., 2010. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res, 70(14):5923-5930.

[49]WilsonC, NimickM, NehoffH, et al., 2017. ALK and IGF-1R as independent targets in crizotinib resistant lung cancer. Sci Rep, 7:13955.

[50]XieXM, HsuJL, ChoiMG, et al., 2009. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther, 8(8):2375-2382.

[51]XiongSD, ZhengYJ, JiangP, et al., 2011. MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci, 7(6):805-814.

[52]ZhangBY, WangO, QinJC, et al., 2013. cis-Acting elements and trans-acting factors in the transcriptional regulation of Raf kinase inhibitory protein expression. PLoS ONE, 8(12):e83097.

[53]ZhangEB, YinDD, SunM, et al., 2014. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. Cell Death Dis, 5(5):e1243.

[54]ZhangR, WangQ, ZhangL, et al., 2015. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B. Front Med, 9(1):90-99.

[55]ZhaoJJ, WangKL, LiaoZY, et al., 2015. Promoter mutation of tumor suppressor microRNA-7 is associated with poor prognosis of lung cancer. Mol Clin Oncol, 3(6):‍1329-1336.

[56]ZhaoJJ, ChuFY, XuHL, et al., 2021. C/EBPα/miR-7 controls CD⁴⁺ T-cell activation and function and orchestrates experimental autoimmune hepatitis in mice. Hepatology, 74(1):379-396.

[57]ZhaoX, YangJ, HuangRY, et al., 2021. The role and its mechanism of intermittent fasting in tumors: friend or foe? Cancer Biol Med, 18(1):63-73.

[58]ZhuangXB, ZhaoC, LiJY, et al., 2019. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Cancer Med, 8(6):2858-2866.